Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesLack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n = 647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study
European Journal of Cancer, 06/26/09
Willemoe GL et al. - In a study to determine whether the benefit of epirubicin vs methotrexate differs according to tissue inhibitor of metalloproteinases 1 (TIMP-1) tumour cell immunoreactivity, it was reported that lack of TIMP-1 tumour cell immunoreactivity seems to predict a favourable effect of epirubicin-containing adjuvant therapy in primary breast cancer.
Methods- Tissue micro arrays from 647 pts randomly assigned to CMF or CEF in DBCG trial 89D were included.
- Primary endpoint was invasive disease-free survival (IDFS).
- A central assessment of TIMP-1 status was performed using immunohistochemistry (IHC).
- Tumours were regarded as TIMP-1-positive if epithelial breast cancer cells were stained using the anti-TIMP-1 monoclonal antibody VT7.
- By central assessment, 75% of tumours were classified as tumour cell TIMP-1-positive.
- Among CEF-treated pts, individuals with TIMP-1-negative tumours had a significantly longer IDFS than pts with TIMP-1-positive tumours.
- The multivariate Cox regression analysis of IDFS showed that CEF was superior to CMF among pts with TIMP-1-negative tumours, while no significant difference could be demonstrated among pts with TIMP-1-positive tumours.
- A non-significant TIMP-1 status (positive or negative) vs treatment (CMF or CEF) interaction was detected for IDFS and OS.
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Angiosarcoma of the Breast: A Rare Clinicopathological Entity
American Journal of Clinical Oncology, 12/07/09
Gene expression of ERbeta isoforms in laser microdissected human breast cancers: Implications for gene expression analyses
Cellular Oncology, 12/07/09
Co-expression of plexin-B1 and Met in human breast and ovary tumours enhances the risk of progression
Cellular Oncology, 12/07/09
Sponsor
Article Search
Sponsor
Sponsor